ArticleBMC infectious diseases2026
Construction of a novel prognostic model for severe fever with thrombocytopenia syndrome patients based on inflammatory indicators.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo identify risk factors associated with poor prognosis in patients with severe fever with thrombocytopenia syndrome (SFTS) and develop a prognostic model based on these factors.
methodsA retrospective analysis was conducted on 207 patients with SFTS admitted to Tongji Hospital from April 1, 2023, to July 18, 2024. Patients were categorized into survival (n = 133) and death (n = 74) groups based on their prognosis. Univariate and multivariate logistic regression analyses were performed to identify independent predictors of mortality, incorporating demographic characteristics and inflammatory biomarkers measured within 24 h of hospital admission. A nomogram model was constructed using R software based on the regression coefficients of the identified predictors. The model's discriminative ability was evaluated using the receiver operating characteristic (ROC) curve, with the area under the curve (AUC) and concordance index (C-index) calculated. Internal validation was performed using the Bootstrap resampling method (1,000 iterations).Furthermore, an external validation cohort comprising 55 patients with SFTS admitted to our hospital between August 2024 and February 2025 was retrospectively collected to evaluate the model's generalizability and stability.
resultsAge, viral load, procalcitonin (PCT), and interleukin-10 (IL-10) were identified as independent risk factors for poor prognosis. A nomogram model incorporating these four factors demonstrated robust predictive performance, yielding an AUC of 0.905 (95% CI, 0.862-0.949; P < 0.001).Internal and external validations confirmed the model's stability and strong prognostic performance in patients with SFTS. Decision curve analysis (DCA) showed that the nomogram yielded a higher net benefit over a wider threshold probability range than previous models in predicting SFTS mortality.
conclusionThis study provides a novel prognostic model for SFTS patients, which may aid in early risk stratification. However, its clinical utility and generalizability need to be further validated in larger cohorts. CLINICAL TRIAL: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.